60 DEGREES PHARMACEUTICALS, INC. (SXTP) - Dilution Analysis

10-Q filing | 2.7M shares outstanding

10-K filing | 2.6M shares outstanding

8-K filing: Stock split 1-for-4 | Outstanding: 1,472,891 → 368,222

10-Q filing | 1.5M shares outstanding

8-K filing: 60 Degrees Pharmaceuticals, Inc. closed an offering on July 16, 2025, involving the sale of 1,753,314 shares of common stock, 878,264 pre-funded warrants, Series A-1 warrants to purchase 878,264 shares, and Series A-2 warrants to purchase 878,264 shares, with a combined offering price of $1.90 per share/warrant and $1.899 per pre-funded warrant/warrant, resulting in gross proceeds of approximately $5.0 million. ($5.0M proceeds)

S-1 filing: 60 Degrees Pharmaceuticals, Inc. is offering shares of common stock and pre-funded warrants along with accompanying warrants, to raise capital for general corporate purposes including working capital.

10-Q filing | 1.5M shares outstanding

S-1/A filing: This prospectus relates to the resale of up to an aggregate of 747,200 shares of common stock of 60 Degrees Pharmaceuticals, Inc., by the selling stockholders named elsewhere in this prospectus.

10-K filing | 1.5M shares outstanding

S-1 filing: This prospectus relates to the resale, from time to time, of up to an aggregate of 3,735,977 shares of common stock of 60 Degrees Pharmaceuticals, Inc., by the selling stockholders named elsewhere in this prospectus.

8-K filing: 60 Degrees Pharmaceuticals, Inc. sold 1,503,500 shares of common stock at $0.715 per share in a registered direct offering, and issued warrants to purchase up to 1,503,500 shares at an exercise price of $0.59 per share. ($1.08M proceeds)

8-K filing: 60 Degrees Pharmaceuticals, Inc. sold 1,021,549 shares of common stock at $1.021 per share in a registered direct offering and issued warrants to purchase up to 2,043,098 shares at an exercise price of $0.771 per share. ($1.04M proceeds)

10-Q filing | 2.4M shares outstanding

S-3 filing: This prospectus relates to the offer and sale from time to time, on a resale basis, by the selling stockholders identified herein or their permitted transferees, of up to an aggregate of 8,913,044 shares of our common stock, par value $0.0001 per share.

8-K filing: 60 Degrees Pharmaceuticals, Inc. completed a private placement on September 5, 2024, issuing 2,898,551 pre-funded warrants, Series A warrants to purchase up to 2,898,551 shares, and Series B warrants to purchase up to 2,898,551 shares for gross proceeds of approximately $4 million. ($12.0M proceeds)

10-Q filing | 1.8M shares outstanding

8-K filing: Stock split 1-for-12 | Outstanding: 11,762,578 → 980,214

S-3 filing: 60 Degrees Pharmaceuticals, Inc. files an S-3 to offer common stock, preferred stock, and debt securities for an aggregate initial offering price not exceeding $15,000,000. A concurrent ATM offering is filed to sell shares of common stock having an aggregate offering price of up to $1,253,603.

10-Q filing | 12.1M shares outstanding

10-K filing | 11.6M shares outstanding

S-1 filing: 60 Degrees Pharmaceuticals, Inc. is offering units, each consisting of one share of common stock and one warrant, and pre-funded units, each consisting of one pre-funded warrant and one warrant.

10-Q filing | 5.3M shares outstanding

10-Q filing | 5.8M shares outstanding

S-1/A filing: This is a firm commitment initial public offering of 1,415,095 units of 60 Degrees Pharmaceuticals, Inc. Each Unit consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share, and one non-tradeable warrant to purchase one share of our common stock at an exercise price of $6.36 per share.

S-1/A filing: 60 Degrees Pharmaceuticals, Inc. is offering 1,415,095 Units, each Unit consisting of one share of common stock, one Tradeable Warrant to purchase one share of common stock and one Non-tradeable Warrant to purchase one share of common stock with a public offering price of $5.30 per Unit.

S-1/A filing: This is an S-1/A filing for an initial public offering to fund the development of new indications for the company's products, repay debt, increase capitalization and financial flexibility, increase visibility, and create a public market for its common stock.

S-1/A filing: This S-1/A filing outlines a proposed offering of Units, each consisting of one share of common stock, one Tradeable Warrant, and one Non-tradeable Warrant, alongside a resale offering by certain stockholders and the issuance of preferred shares to Knight Therapeutics in exchange for debt extinguishment.

S-1/A filing: This S-1/A filing outlines a proposed offering to fund the development of new indications for the company's products, particularly a COVID-19 clinical trial, repay debt, and increase capitalization.

S-1 filing: The principal purposes of this offering are to fund the development of new indications for our products with a focus on executing a COVID-19 clinical trial involving Arakoda, to repay debt associated with prior financing, increase our capitalization and financial flexibility, increase our visibility in the marketplace and create a public market for our common stock.